Back to results
US 11,845,964 B2Granted
Bacteria engineered to treat diseases associated with hyperammonemia
AssigneeSynlogic Operating Company, Inc.
InventorsDean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
Life of this patent
Estimating the term…
Abstract
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Claims20
A method of treating a hyperammonemia-associated disorder or symptom(s) thereof in a subject in need thereof comprising administering to the subject a genetically engineered bacterium comprising:
- a gene encoding an arginine feedback resistant N-acetylglutamate synthetase (ArgAfbr), wherein the ArgAfbr has reduced arginine feedback inhibition as compared to a wild-type N-acetylglutamate synthetase from the same bacterial subtype under the same conditions and wherein the gene encoding ArgAfbr is operably linked to a promoter that is induced by low-oxygen or anaerobic conditions,
- wherein the bacterium has been genetically engineered to lack a functional ArgR,
- for a period of time sufficient to treat the hyperammonemia-associated disorder or the symptom(s) thereof.
Dependencies are inferred from the claim text.